Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to 'buzz' smoke by HPLC/MS/MS

Biomedical Chromatography

Volumn 26, Issue 11, 2012, Pages 1393-1398

  Poklis, Justin L ^a   Amira, Dorra ^a,b   Wise, Laura E ^a   Wiebelhaus, Jason M ^a   Haggerty, Brenda J ^a   Lichtman, Aron H ^a   Poklis, Alphonse ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Herbal Incense product; HPLC MS MS; JWH 018

Indexed keywords

BLOOD; BRAIN; ELECTROSPRAY IONIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE EFFECTS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MAMMALS; ODORS; PHYSIOLOGICAL MODELS;

BLOOD AND TISSUES; CANNABIMIMETIC; HERBAL INCENSE PRODUCT; HPLC-MS-MS; INHALATION EXPOSURE; INTERNAL STANDARDS; JWH-018; LIQUID-LIQUID EXTRACTION; METHANONE; TRIPLE-QUADRUPOLE MASS SPECTROMETER;

SMOKE;

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; ACETONITRILE; CANNABINOID RECEPTOR; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD LEVEL; BODY TEMPERATURE; CATALEPSY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSPRAY; EXPOSURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERREFLEXIA; INHALATION; LIQUID; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; MOUSE; NONHUMAN; PTOSIS; QUALITY CONTROL; SEPARATION TECHNIQUE; STANDARD; TISSUES;

MUS;

EID: 84867142214     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2710     Document Type: Article

References (35)

1. Aceto MD, Scates SM, Razdan RK and Martin BR. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. Journal of Pharmacology and Experimental Therapy 1998; 287: 598-605.
2. Atwood BK, Huffman JW, Straiker A and Mackie K. JWH-018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. British Journal of Pharmacology 2010; 160: 585-593. DOI: 10.1111/j.1476-5381.2009.00582.x
3. Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME and Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug and Alcohol Dependence 2000; 60: 133-140. DOI: 10.1016/S0376-8716(99)00152-0
4. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M and Ferreirós N. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry 2009; 44: 832-837. DOI: 10.1002/jms.1558
5. Compton DR, Johnson MR, Melvin LS and Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. Journal of Pharmacology and Experimental Therapy 1992; 260: 201-209.
6. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR and Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Science USA 2001; 98: 9371-9376. DOI: 10.1073/pnas.161191698
7. Cutler MG, Mackintosh JH and Chance MR. Effects of cannabis resin on social behavior in the laboratory mouse. Psychopharmacologia 1975; 41: 271-276.
8. Drug Enforcement Administration. Scheduling update. Microgram Bulletin 2010; 44: 1.
9. European Monitoring Centre for Drugs and Drug Addiction. Action on new drugs briefing paper: understanding the Spice phenomenon (a report from an EMCDDA expert meeting, 6 March 2009, Lisbon), 2009. Available from: http://www.emcdda.europa.edu/html.cfm/index78154EN.html (accessed 25 May 2010).
10. Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M, Nosyrev A, Vedenin A, Izotov B, Zabirovac I and Rozhanets V. Chromatography-mass-spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking. Journal of Chromatography B 2011; 879: 1126-1136. DOI: 10.1016/j.jchromb.2011.03.034
11. Hudson S, Ramsey J, King L, Maynard S, Dargan PJ and Wood DM. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabimimetics in 'Herbal High' products. Journal of Analytical Toxicology 2010; 24: 252-260.
12. Huffman JW and Dai D. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorganic & Medicinal Chemistry Letters 1994; 4: 563-566.
13. Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL and Martin BR. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorganic & Medicinal Chemistry Letters 2005; 15: 4110-4113. DOI: 10.1016/j.bmcl.2005.06.008
14. Jacob JJ, Ramabadran K and Campos-Medeiros M. A pharmacological analysis of levonantradol antinociception in mice. Journal of Clinical Pharmacology 1981; 21: 327S-333S.
15. Lichtman AH, Poklis JL, Wilson DM, Poklis A and Martin BR. The pharmacological activity of inhalation exposure to marijuana in mice. Drug and Alcohol Dependence 2001; 63: 107-116. DOI: 10.1016/S0376-8716(00)00205-2
16. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggerman M, Ernst L and Beuerle T. Spice: a never ending story? Forensic Science International 2009; 191: 58-63. DOI: 10.1016/j.forsciint.2009.06.008
17. Little JP, Compton DR, Johnson MR, Melvin LS and Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. Journal of Pharmacology and Experimental Therapy 1988; 247: 1046-1051.
18. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL and Cravatt BF. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the National Academy of Science USA 2009; 106: 20270-20275. DOI: 10.1073/pnas.0909411106
19. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R and Ward SJ. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology, Biochemistry, and Behavior 1991; 40: 471-478.
20. Patel S and Hillard CJ. Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. Journal of Pharmacology and Experimental Therapy 2001; 297: 629-637.
21. 9-tetrahydrocannabinol and its metabolites in mice brain following marijuana inhalation determined by HPLC/MS/MS. Analytical Toxicology 2010; 34: 516-520
22. Sebastian D, Kneisel S, Weinmann W, Zimmermann R and Auwärter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. Journal of Mass Spectrometry 2011; 46: 163-171. DOI: 10.1002/jms.1877
23. Simmons J, Cookman L and Skinner C. Three cases of 'spice' exposure. Clinical Toxicology 2011; 49 431-433. DOI: 10.3109/15563650.2011.584316
24. Sobolevsky T, Prasolov I and Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Science International 2010; 200: 141-147. DOI: 10.1016/j.forsciint.2010.04.003
25. Teske T, Weller J, Fieguth A, Rothamel T, Schulz Y and Troger HD. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalene-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2010; 878: 2659-2663. DOI: 10.1016/j.jchromb.2010.03.016
26. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y and Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chemical and Pharmaceutical Bulletin 2009a; 57: 439-441. DOI: 10.1248/cpb.57.439
27. Uchiyama N, Kikura-Hanajiri R, Kawahara N and Goda Y. Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicology 2009b; 27: 61-66. DOI: 10.1007/s11419-009-0069-y
28. Uchiyama N, Kikura-Hanajiri R, Ogata J and Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Science International 2010; 198: 31-38. DOI: 10.1016/j.forsciint.2010.01.004
29. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH and Martin BR. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berlin) 2006; 186: 226-234. DOI: 10.1007/s00213-006-0356-9
30. Weissmann A, Milne GM and Melvin LS. Cannabimimetic activity from CP-47, 497, a derivative of 3-phenylcyclohexanol. Journal of Pharmacology and Experimental Therapy 1982; 223: 516-523.
31. Wiley JL, Compton DR, Dai D, Hoffman JW and Martin BR. Structure-activity relationships of indole and pyrrole-derived cannabinoids. Journal of Pharmacology and Experimental Therapy 1998; 285: 994-1004.
32. Wiley JL, Kendler SH, Burston JJ, Howard DR, Selley DE and Sim-Selley LJ. Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology 2008; 55: 1183-1190. DOI: 10.1124/jpet.107.130328
33. Wise LE, Shelton CC, Cravatt BF, Martin BR and Lichtman AH. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. European Journal of Pharmacology 2007; 557: 44-48. DOI: 10.1016/j.ejphar.2006.11.002
34. Zhang Q, Ma P and Cole RB. Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Analytical and Bioanalytical Chemistry 2006; 386: 1345-1355. DOI: 10.1007/s00216-006-0717-6
35. Zuba D, Byrska B and Maclow M. Comparison of 'Herbal Highs' composition. Analytical and Bioanalytical Chemistry 2011; 400: 119-126. DOI: 10.1007/s00216-011-4743